Mara G. Coyle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mara G. Coyle has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Abbot Laptook
Department of Pediatrics, Women and Infants Hospital, Providence, RI, USA
1 shared publication- Amy L. Salisbury
Brown Center for the Study of Children at Risk, Women and Infants' Hospital, Providence, RI, USA; Department of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, RI, USA; Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI, USA
1 shared publication Barry Lester
Department of Pediatrics, Women and Infants Hospital, Providence, USA
1 shared publicationEunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Networ
1 shared publication- Gabriele Fischer
Medical University of Vienna
1 shared publication - Hendree E. Jones
Department of Obstetrics and Gynecology University of North Carolina School of Medicine Chapel Hill North Carolina USA
1 shared publication
Latest Publications
- Open Access
- 15 October 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 45 (4) , 465-472
Prediction of site-specific pharmacologic therapy among newborns with neonatal opioid withdrawal syndrome
Objective To predict pharmacotherapy for NOWS based on factors available shortly after birth. Study design A multi-center, retrospective study of 1377 opioid exposed newborns between 2016 and 2017 dichotomized based on pharmacologic treatment (N = 665 treated, N = 712 not treated) was conducted. A multilevel mixed-effect logistic regression model that considered cluster effect from sites determined significant maternal and newborn factors associated with pharmacotherapy, which were combined in a nomogram to predict probability of treatment for infants at each participating site. Results Factors predictive of treatment were: no breastmilk (1.76, 1.30–2.39; p < 0.001), male sex (1.39, 1.05–1.83; p = 0.021), polysubstance exposure (1.53, 1.15–2.06; p = 0.004), inadequate prenatal care (1.51, 1.07–2.13; p < 0.018) and Methadone (6.08, 4.03–9.27; p < 0.001) or Buprenorphine (1.86, 1.29–2.69; p < 0.001). A site-specific nomogram provided the probability of treatment for individual newborns. Conclusion Six factors available shortly after birth can be combined to predict site-specific use of medication for NOWS. If confirmed, the nomogram may identify at-risk newborns.
- 15 October 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 45 (4) , 465-472
Open AccessPrediction of site-specific pharmacologic therapy among newborns with neonatal opioid withdrawal syndrome
Objective To predict pharmacotherapy for NOWS based on factors available shortly after birth. Study design A multi-center, retrospective study of 1377 opioid exposed newborns between 2016 and 2017 dichotomized based on pharmacologic treatment (N = 665 treated, N = 712 not treated) was conducted. A multilevel mixed-effect logistic regression model that considered cluster effect from sites determined significant maternal and newborn factors associated with pharmacotherapy, which were combined in a nomogram to predict probability of treatment for infants at each participating site. Results Factors predictive of treatment were: no breastmilk (1.76, 1.30–2.39; p < 0.001), male sex (1.39, 1.05–1.83; p = 0.021), polysubstance exposure (1.53, 1.15–2.06; p = 0.004), inadequate prenatal care (1.51, 1.07–2.13; p < 0.018) and Methadone (6.08, 4.03–9.27; p < 0.001) or Buprenorphine (1.86, 1.29–2.69; p < 0.001). A site-specific nomogram provided the probability of treatment for individual newborns. Conclusion Six factors available shortly after birth can be combined to predict site-specific use of medication for NOWS. If confirmed, the nomogram may identify at-risk newborns.
- 22 November 2018
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 4 (1) , 47
Neonatal abstinence syndrome
Neonatal abstinence syndrome refers to the signs and symptoms attributed to the cessation of prenatal exposure (via placental transfer) to various substances. This Primer focuses on neonatal abstinence syndrome caused by opioid use during pregnancy — neonatal opioid withdrawal syndrome (NOWS). As the global prevalence of opioid use has alarmingly increased, so has the incidence of NOWS. NOWS can manifest with varying severity or not at all, for unknown reasons, but is likely to be associated with multiple factors, both maternal (for example, smoking and additional substance exposures) and neonatal (gestational age, sex and genetics). Care for the infant with NOWS begins with addressing the issues experienced by pregnant women with opioid use disorder. Co-occurring mental illness, economic hardship, intimate partner violence, infectious diseases and limited access to care are common in these women and can result in poor maternal and neonatal outcomes. Although there is no consensus regarding optimal NOWS management, non-pharmacological interventions (such as breastfeeding and rooming-in of the mother and the baby) have become a priority, as they can ameliorate symptoms without the need for further opioid exposure. Untreated NOWS can be associated with morbidity in early infancy, and the long-term consequences of fetal opioid exposure are only beginning to be understood.
- 22 November 2018
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 4 (1) , 47
Neonatal abstinence syndrome
Neonatal abstinence syndrome refers to the signs and symptoms attributed to the cessation of prenatal exposure (via placental transfer) to various substances. This Primer focuses on neonatal abstinence syndrome caused by opioid use during pregnancy — neonatal opioid withdrawal syndrome (NOWS). As the global prevalence of opioid use has alarmingly increased, so has the incidence of NOWS. NOWS can manifest with varying severity or not at all, for unknown reasons, but is likely to be associated with multiple factors, both maternal (for example, smoking and additional substance exposures) and neonatal (gestational age, sex and genetics). Care for the infant with NOWS begins with addressing the issues experienced by pregnant women with opioid use disorder. Co-occurring mental illness, economic hardship, intimate partner violence, infectious diseases and limited access to care are common in these women and can result in poor maternal and neonatal outcomes. Although there is no consensus regarding optimal NOWS management, non-pharmacological interventions (such as breastfeeding and rooming-in of the mother and the baby) have become a priority, as they can ameliorate symptoms without the need for further opioid exposure. Untreated NOWS can be associated with morbidity in early infancy, and the long-term consequences of fetal opioid exposure are only beginning to be understood.
- Open Access
- 1 April 2018
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 185, 40-49
Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes
- 1 April 2018
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 185, 40-49
Open AccessPrenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes